JNJ, BioCrossroads invest in Hoosier pharma startup at work on potential hepatitis B cure

An Indiana University spinout attracted investors from Johnson & Johnson Development Corp. and BioCrossroads with novel drugs to treat, and even potentially cure, patients with hepatitis B. Assembly Pharmaceuticals received an undisclosed amount for this seed round. This funding will finance the preclinical proof of concept and help the company establish its bio labs in San Francisco, […]


Alzheimer’s disease treatment uses anti-seizure meds to slow memory loss

An Indiana neuroscience pharmaceutical company hopes it can gain entry into the market for Alzheimer’s disease treatment with experimental drugs it thinks could prevent the progression of the disease in the growing population of seniors. Based on the work of Dr. Michela Gallagher of John Hopkins University, AgeneBio of Indianapolis is working to slow the […]